Xyzagen offers a range of services including pharmacokinetics analysis, bioanalysis of small molecules, compound screening, and dose rationale guidance. They utilize microsampling capabilities to combine pharmacokinetic and behavioral endpoints for a better understanding of a drug's exposure-response relationship. Xyzagen also provides modeling and simulation to predict a drug's exposure in larger animals, saving time and money in toxicology studies. With experienced consultants in nonclinical and clinical pharmacology, Xyzagen has been involved in numerous IND and NDA submissions. They also offer a gap analysis approach to determine if a program is ready for submission to the FDA.